Barry Canton
CIK 1882756 · last filed 2026-07-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DNA.WS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
27 DRYDOCK AVENUE, 8TH FLOOR
BOSTON, MA 02210
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DNA | 10%+ Owner | 801,261 | $9.70 | $7.77M | -$977.6K | 3 | 2026-07-30 |
| Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | 10%+ Owner | 24,749,098 | $0.01 | $155.9K | -$59.76M | 91 | 2024-04-29 |
Recent Filings · Page 4 of 14
134 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-06 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Sell (S) | −75,300 | -$123.6K | EDGAR |
| 2023-10-05 | DNA | Notice (144) | −37,650 | -$62.3K | EDGAR |
| 2023-09-29 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Sell (S) | −75,300 | -$134.8K | EDGAR |
| 2023-09-28 | DNA | Notice (144) | −37,650 | -$67.4K | EDGAR |
| 2023-09-22 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Sell (S) | −75,300 | -$135.7K | EDGAR |
| 2023-09-21 | DNA | Notice (144) | −37,650 | -$67.4K | EDGAR |
| 2023-09-15 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Sell (S) | −75,300 | -$152.1K | EDGAR |
| 2023-09-14 | DNA | Notice (144) | −37,650 | -$76.1K | EDGAR |
| 2023-09-08 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Sell (S) | −75,300 | -$164.1K | EDGAR |
| 2023-09-07 | DNA | Notice (144) | −37,650 | -$82.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.